{"count": 20, "results": [{"_id": "32660971", "pmid": 32660971, "title": "The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.", "journal": "J Am Soc Nephrol", "authors": ["Shin JI", "Sang Y", "Chang AR", "Dunning SC", "Coresh J", "Inker LA", "Selvin E", "Ballew SH", "Grams ME"], "date": "2020-08-01T00:00:00Z", "doi": "10.1681/ASN.2019101119", "meta_date_publication": "2020 Aug", "meta_volume": "31", "meta_issue": "8", "meta_pages": "1847-1858", "score": 50276.855, "text_hl": "The FDA @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Label Change and Racial and Sex Disparities in @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Prescription among @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@.", "citations": {"NLM": "Shin JI, Sang Y, Chang AR, Dunning SC, Coresh J, Inker LA, Selvin E, Ballew SH, Grams ME. The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD. J Am Soc Nephrol. 2020 Aug;31(8):1847-1858. PMID: 32660971", "BibTeX": "@article{32660971, title={The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.}, author={Shin JI and Sang Y and Chang AR and Dunning SC and Coresh J and Inker LA and Selvin E and Ballew SH and Grams ME}, journal={J Am Soc Nephrol}, volume={31}, number={8}, pages={1847-1858}}"}}, {"_id": "39665726", "pmid": 39665726, "title": "Metformin in People With Diabetes and Advanced CKD: Should We Dare?", "journal": "Am J Kidney Dis", "authors": ["Shin JI", "Créon A", "Carrero JJ"], "date": "2024-12-10T00:00:00Z", "doi": "10.1053/j.ajkd.2024.10.004", "meta_date_publication": "2024 Dec 10", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50276.402, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in People With @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ and Advanced @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@: Should We Dare?", "citations": {"NLM": "Shin JI, Créon A, Carrero JJ. Metformin in People With Diabetes and Advanced CKD: Should We Dare? Am J Kidney Dis. 2024 Dec 10;():. PMID: 39665726", "BibTeX": "@article{39665726, title={Metformin in People With Diabetes and Advanced CKD: Should We Dare?}, author={Shin JI and Créon A and Carrero JJ}, journal={Am J Kidney Dis}}"}}, {"_id": "32936781", "pmid": 32936781, "title": "The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD Injury.", "journal": "J Am Soc Nephrol", "authors": ["Rutkowski MP"], "date": "2020-11-01T00:00:00Z", "doi": "10.1681/ASN.2020071061", "meta_date_publication": "2020 Nov", "meta_volume": "31", "meta_issue": "11", "meta_pages": "2740", "score": 50275.305, "text_hl": "The FDA @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Label Change and Racial and Sex Disparities in @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Prescription among @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD Injury@@@.", "citations": {"NLM": "Rutkowski MP. The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD Injury. J Am Soc Nephrol. 2020 Nov;31(11):2740. PMID: 32936781", "BibTeX": "@article{32936781, title={The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD Injury.}, author={Rutkowski MP}, journal={J Am Soc Nephrol}, volume={31}, number={11}, pages={2740}}"}}, {"_id": "33594488", "pmid": 33594488, "title": "Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial.", "journal": "Osteoporos Int", "authors": ["Nordklint AK", "Almdal TP", "Vestergaard P", "Lundby-Christensen L", "Boesgaard TW", "Breum L", "Gade-Rasmussen B", "Sneppen SB", "Gluud C", "Hemmingsen B", "Perrild H", "Madsbad S", "Mathiesen ER", "Tarnow L", "Thorsteinsson B", "Vestergaard H", "Lund SS", "Eiken P"], "date": "2021-09-01T00:00:00Z", "doi": "10.1007/s00198-021-05870-1", "meta_date_publication": "2021 Sep", "meta_volume": "32", "meta_issue": "9", "meta_pages": "1837-1848", "score": 50243.625, "text_hl": "Some studies indicate potential beneficial effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on body composition and bone. ", "citations": {"NLM": "Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L, Gade-Rasmussen B, Sneppen SB, Gluud C, Hemmingsen B, Perrild H, Madsbad S, Mathiesen ER, Tarnow L, Thorsteinsson B, Vestergaard H, Lund SS, Eiken P. Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporos Int. 2021 Sep;32(9):1837-1848. PMID: 33594488", "BibTeX": "@article{33594488, title={Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial.}, author={Nordklint AK and Almdal TP and Vestergaard P and Lundby-Christensen L and Boesgaard TW and Breum L and Gade-Rasmussen B and Sneppen SB and Gluud C and Hemmingsen B and Perrild H and Madsbad S and Mathiesen ER and Tarnow L and Thorsteinsson B and Vestergaard H and Lund SS and Eiken P}, journal={Osteoporos Int}, volume={32}, number={9}, pages={1837-1848}}"}}, {"_id": "37648574", "pmid": 37648574, "title": "Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.", "journal": "Clin Ther", "authors": ["Anson M", "Zhao SS", "Essa H", "Austin P", "Ibarburu GH", "Lip GYH", "Alam U"], "date": "2023-08-28T00:00:00Z", "doi": "10.1016/j.clinthera.2023.07.026", "meta_date_publication": "2023 Aug 28", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50243.543, "text_hl": "A total of 98,094 individuals were included in the core analysis. The @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ only group had a greater risk of mortality (RR 1.44, [95% CI 1.34-1.55], P<0.0001), @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ (RR 1.10, [95% CI 1.04-1.16], P = 0.0004), @DISEASE_Diabetic_Nephropathies @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@ (RR 1.06, [95% CI 1.01-1.12], P = 0.0239), @DISEASE_Heart_Failure @DISEASE_MESH:D006333 @@@heart failure@@@ (RR 1.13, [95% CI 1.07-1.21], P < 0.0001) and hospitalisation (RR 1.24, [95% CI 1.21-1.27], P < 0.0001) compared to individuals treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and SGLT2i. ", "citations": {"NLM": "Anson M, Zhao SS, Essa H, Austin P, Ibarburu GH, Lip GYH, Alam U. Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity. Clin Ther. 2023 Aug 28;():. PMID: 37648574", "BibTeX": "@article{37648574, title={Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.}, author={Anson M and Zhao SS and Essa H and Austin P and Ibarburu GH and Lip GYH and Alam U}, journal={Clin Ther}}"}}, {"_id": "32276962", "pmid": 32276962, "title": "Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.", "journal": "J Am Soc Nephrol", "authors": ["Packer M"], "date": "2020-05-01T00:00:00Z", "doi": "10.1681/ASN.2020010010", "meta_date_publication": "2020 May", "meta_volume": "31", "meta_issue": "5", "meta_pages": "907-919", "score": 50229.188, "text_hl": "Importantly, because @GENE_INS @GENE_3630 @@@insulin@@@ acts to depress autophagic flux, these derangements in nutrient deprivation signaling are not ameliorated by antihyperglycemic drugs that enhance @GENE_INS @GENE_3630 @@@insulin@@@ secretion or signaling. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ is an established @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@ agonist that can promote autophagy, but its effects on the course of @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@ have been demonstrated only in the experimental setting. ", "citations": {"NLM": "Packer M. Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors. J Am Soc Nephrol. 2020 May;31(5):907-919. PMID: 32276962", "BibTeX": "@article{32276962, title={Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.}, author={Packer M}, journal={J Am Soc Nephrol}, volume={31}, number={5}, pages={907-919}}"}}, {"_id": "24698854", "pmid": 24698854, "title": "Metformin OK in CKD?", "journal": "Drug Ther Bull", "date": "2014-04-01T00:00:00Z", "doi": "10.1136/dtb.2014.4.0244", "meta_date_publication": "2014 Apr", "meta_volume": "52", "meta_issue": "4", "meta_pages": "37", "score": 50092.027, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ OK in @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@?", "citations": {"NLM": "Metformin OK in CKD? Drug Ther Bull. 2014 Apr;52(4):37. PMID: 24698854", "BibTeX": "@article{24698854, title={Metformin OK in CKD?}, journal={Drug Ther Bull}, volume={52}, number={4}, pages={37}}"}}, {"_id": "26593314", "pmid": 26593314, "title": "Restricting Metformin in CKD: Continued Caution Warranted.", "journal": "Am J Kidney Dis", "authors": ["Rhee CM", "Kalantar-Zadeh K"], "date": "2015-12-01T00:00:00Z", "doi": "10.1053/j.ajkd.2015.07.039", "meta_date_publication": "2015 Dec", "meta_volume": "66", "meta_issue": "6", "meta_pages": "1101-2", "score": 50081.64, "text_hl": "Restricting @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@: Continued Caution Warranted.", "citations": {"NLM": "Rhee CM, Kalantar-Zadeh K. Restricting Metformin in CKD: Continued Caution Warranted. Am J Kidney Dis. 2015 Dec;66(6):1101-2. PMID: 26593314", "BibTeX": "@article{26593314, title={Restricting Metformin in CKD: Continued Caution Warranted.}, author={Rhee CM and Kalantar-Zadeh K}, journal={Am J Kidney Dis}, volume={66}, number={6}, pages={1101-2}}"}}, {"_id": "26593315", "pmid": 26593315, "title": "In Reply to 'Restricting Metformin in CKD: Continued Caution Warranted'.", "journal": "Am J Kidney Dis", "authors": ["Stanton RC"], "date": "2015-12-01T00:00:00Z", "doi": "10.1053/j.ajkd.2015.09.012", "meta_date_publication": "2015 Dec", "meta_volume": "66", "meta_issue": "6", "meta_pages": "1102", "score": 50079.16, "text_hl": "In Reply to 'Restricting @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in @<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD@@@: Continued Caution Warranted'.", "citations": {"NLM": "Stanton RC. In Reply to 'Restricting Metformin in CKD: Continued Caution Warranted'. Am J Kidney Dis. 2015 Dec;66(6):1102. PMID: 26593315", "BibTeX": "@article{26593315, title={In Reply to 'Restricting Metformin in CKD: Continued Caution Warranted'.}, author={Stanton RC}, journal={Am J Kidney Dis}, volume={66}, number={6}, pages={1102}}"}}, {"_id": "24752835", "pmid": 24752835, "title": "Use of metformin in diseases of aging.", "journal": "Curr Diab Rep", "authors": ["Miles JM", "Rule AD", "Borlaug BA"], "date": "2014-06-01T00:00:00Z", "doi": "10.1007/s11892-014-0490-4", "meta_date_publication": "2014 Jun", "meta_volume": "14", "meta_issue": "6", "meta_pages": "490", "score": 50071.227, "text_hl": "Evidence has accumulated indicating that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is safe in people with @DISEASE_Kidney_Failure_Chronic @DISEASE_MESH:D007676 @@@stage 3 chronic kidney disease@@@ (@<m>DISEASE_Chronic_Kidney_Disease_Mineral_and_Bone_Disorder</m> @DISEASE_MESH:D012080 @@@CKD-3@@@). ", "citations": {"NLM": "Miles JM, Rule AD, Borlaug BA. Use of metformin in diseases of aging. Curr Diab Rep. 2014 Jun;14(6):490. PMID: 24752835", "BibTeX": "@article{24752835, title={Use of metformin in diseases of aging.}, author={Miles JM and Rule AD and Borlaug BA}, journal={Curr Diab Rep}, volume={14}, number={6}, pages={490}}"}}]}